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Abstract
We consider the problem of testing for a dose-related effect based on a candidate set of (typ-
ically nonlinear) dose-response models using likelihood-ratio tests. For the considered models
this reduces to assessing whether the slope parameter in these nonlinear regression models is
zero or not. A technical problem is that the null distribution (when the slope is zero) depends
on non-identifiable parameters, so that standard asymptotic results on the distribution of the
likelihood-ratio test no longer apply. Asymptotic solutions for this problem have been exten-
sively discussed in the literature. The resulting approximations however are not of simple form
and require simulation to calculate the asymptotic distribution. In addition their appropriate-
ness might be doubtful for the case of a small sample size. Direct simulation to approximate
the null distribution is numerically unstable due to the non identifiability of some parame-
ters. In this article we derive a numerical algorithm to approximate the exact distribution of
the likelihood-ratio test under multiple models for normally distributed data. The algorithm
uses methods from differential geometry and can be used to evaluate the distribution under
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the null hypothesis, but also allows for power and sample size calculations. We compare the
proposed testing approach to the MCP-Mod methodology and alternative methods for testing
for a dose-related trend in a dose-finding example data set and simulations.
1 Introduction
A major objective in the development of a pharmaceutical compound is the characterisation of its
dose-response curve. For this purpose Phase II trials are conducted that compare several doses of
the compound to placebo. Then (typically) nonlinear regression models are used to estimate the
underlying dose-response curve. See for example Bretz et al. (2005); Thomas (2006); Dragalin et al.
(2007); Jones et al. (2011) or Grieve and Krams (2005) for different approaches towards model-based
dose-response analyses in Phase II studies.
Typically the model linking dose and response can be assumed to follow a nonlinear function
of the form α + βxÈ, where α and β are linear parameters describing the placebo response and
the slope parameter, and xÈ is a nonlinear transformation of the dose variable z depending on a
parameter vector È. The major question regarding the dose-response curve that we will consider in
this article is to assess whether there exists a dose-related effect (i.e. a dose-response trend) or not.
For the dose-response function above this reduces to testing the hypothesis of β = 0.
One of the challenges with a dose-response model based approach is that there is model un-
certainty at the design stage of the trial, when the statistical analyses are specified. That means
specifying one particular form of the dose-response curve bears the risk of mis-specification. Naively
one might think that it is valid to apply a model selection procedure to obtain the best model once
one has obtained the data and then perform a test for a dose-related effect, ignoring the fact that
a model selection was performed. However it is known that statistical inference following a model
selection is no longer valid in the sense of not providing confidence intervals of nominal coverage
and resulting in a type I error inflation (Chatfield (1995); Leeb and Po¨tscher (2005), or Chapter
7 of Claeskens and Hjort (2008)). These concerns might have lead to a situation where primarily
ANOVA type methods have been used in Phase II trials, which do not assume a functional rela-
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tionship between dose and response. This, however, comes at a loss in terms of statistical efficiency
but also interpretability of the study results.
A compromise between approaches that make no assumptions on the functional form of the dose-
response curve and those that assume one specific dose-response model is to specify a candidate
set of dose-response models. This is the idea underlying the Multiple Comparison Procedures and
Modeling (MCP-Mod) approach (Bretz et al. (2005); Pinheiro et al. (2014); European Medicines
Agency (2014)). MCP-Mod consists of two steps: testing and estimation. The testing step, which
is of primary interest for this article, is done using multiple linear contrast tests. To derive contrast
tests that are powerful to detect the nonlinear shapes in the candidate set, one needs to pre-specify
the parameters È of the nonlinear part of the regression functions. This approach bears the risk of
model mis-specification (as a È different from the one pre-specified might be adequate).
An alternative approach is to assess the hypothesis β = 0 by using multiple likelihood-ratio
tests. Arguments by Andrews and Ploberger (1995) and Andrews (1996) show that the likelihood-
ratio test will always be admissible in this setting (i.e., there is no test that controls the type-I
error and is uniformly more powerful). A technical problem with such likelihood-ratio tests is that
under the null hypothesis the parameters È of the nonlinear regression models are asymptotically
not identifiable. Therefore, the standard asymptotic results for the null distribution of likelihood-
ratio statistics do no longer apply; see for example Davies (1977), Davies (1987), Andrews and
Ploberger (1994), Ritz and Skovgaard (2005) and Liu and Shao (2003). Dette et al. (2015) derive
the asymptotic null distribution of the likelihood-ratio statistic under multiple models. Baayen
et al. (2015) only consider nested dose-response models, but describe a similar approach, where the
asymptotic distribution for the likelihood-ratio tests is derived explicitly. The resulting asymptotic
distribution is not of a simple form and requires simulation to approximate critical values and
p-values that are asymptotically valid.
We will consider the exact distribution for likelihood-ratio tests for the null hypothesis that no
trend exists against the composite alternative that one of the candidate models is true. We assume
that observations are independent and normally distributed and that the dose-response models are
piece-wise continuous, which is generally true for the models considered in practice.
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To find the small-sample distribution of the likelihood-ratio statistic, one can of course simulate
data and fit the dose-response models under the null hypothesis (β = 0) to obtain critical values for
the test statistic. However, as most of the statistical models considered in this article are nonlinear,
computationally expensive iterative techniques are required to calculate the maximum likelihood
estimates for each model and each simulated data set. Such an approach is also numerically unstable
under β = 0 as the likelihood function will be almost flat with potentially several local maxima for
the non-identifiable parameter È.
In this article, we work with the small-sample distribution of the likelihood-ratio statistic using
methods developed by Hotelling (1939) and Weyl (1939) and reviewed from a statistical perspective
by Johansen and Johnstone (1990). We start with the special case of a single model. For this
special case, Hotelling used a geometric approach to derive the exact null distributions analytically.
We extend these methods to multiple dose-response models and show that, as in the case of a
single model, the distribution is determined by volumes of certain tubular neighborhoods on the
unit sphere. We then present an importance sampling-type algorithm to approximate such volumes
numerically. In particular, this approach does not require the calculation of maximum-likelihood
estimates (with its associated numerical difficulties) in each simulation run. Using this approach,
it is also possible to evaluate the power of the proposed test under alternative hypotheses, thereby
enabling sample-size calculations, which are crucial in clinical development.
The outline of this paper is as follows. After introducing the notation in Section 2.1, we will re-
view the application of Hotelling’s approach for the case of one dose-response model in Section 2.2.2.
We then present the new methodology in Section 2.2.4 and Section 2.3, where a numerical algorithm
is introduced to approximate the distribution of the likelihood-ratio test. In Section 3 we apply the
method to data from a dose-response study and compare the performance of the new method to
MCP-Mod and a number of alternative approaches in a setting motivated by this example data.
Section 4 gives some concluding remarks.
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2 Methods
2.1 Notation
Consider a random vector y containing the clinical measurement of interest for each of the n patients.
Here we assume y ∼ N (µ, σ2In) with n independent, normally distributed observations with an
unknown common standard deviation σ ∈ R+ and an unknown mean vector µ ∈ Rn.
To describe possible forms of the mean vector µ, one selects m candidate dose-response models
of the following partially-linear form
µi(α, β, È) = α1n + β xÈ,i (α, β ∈ R, È ∈ Γi, i = 1, . . . ,m) (1)
where xÈ,i = xÈ,i(z) are nonlinear transformations of the dose variable z. Since the value of z can
be fixed throughout, the dependencies on z will not be explicitly indicated. We assume that the
nonlinear transformations È 7→ xÈ,i : Γi → Rn are piece-wise-continuous functions. One example is
the so-called Emax model
µi(α, β, È) = α + βxÈ, xÈ = z/(z + È), α, β ∈ R, È ∈ Γ = R+;
for more examples, see, e.g., Bornkamp et al. (2009).
Note that for β = 0, the value of È in (1) has no influence on the shape of the model function,
which means that asymptotically the parameter is not identified.
We will consider the hypothesis µ ∈ H0, where
H0 = {α1n : α ∈ R}, (2)
the one-sided alternatives µ ∈ H1, . . . , µ ∈ H2m, where, for i = 1, . . . ,m,
Hi = {µi(α, β, È) : α ∈ R, β ∈ R+, È ∈ Γi}, (3)
Hm+i = {µi(α,−β, È) : α ∈ R, β ∈ R+, È ∈ Γi}, (4)
and the multiple alternatives µ ∈ HI , where
HI =
⋃
i∈I
Hi, for I ⊆ {1, . . . , 2m}. (5)
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For the special cases I = {1, . . . ,m} or I = {m+ 1, . . . , 2m} we get one-sided alternatives, and for
the special case I = {1, . . . , 2m} a two-sided alternative. The goal will be to derive the likelihood-
ratio test for H0 against HI .
2.2 Distribution of the LR test
To illustrate the general approach for calculation of the distribution of the likelihood-ratio test we
will start with the simple setting of a single linear dose-response model first in Section 2.2.1, then
consider a single nonlinear model in Section 2.2.2 and finally present the situation for multiple
dose-response models in Section 2.2.4.
2.2.1 Single linear dose-response model
We first consider the special case of testing H0 against a single hypothesis Hi (so that I = {i}),
where Γi = {Èi} contains a single parameter value Èi. In this case Èi is known and the dose-response
model reduces to a linear regression model. If we define x = xÈi,i, then Hi becomes the hypothesis
β > 0 in the linear model y ∼ N (α1n +βx, σ2In), while H0 states that β = 0. In this case standard
distributional results can be used to calculate the distribution of the LR test statistic for testing
β = 0. The reason, why we present this case here is to motivate a transformation of the standard
LR test statistic that turns out to be useful for subsequent sections.
Appendix A shows that the LR statistic has the form S(R) = (1− 1{R > 0}R2)n/2 with
R = x˜>y˜, where x˜ =
Bx
‖Bx‖ and y˜ =
By
‖By‖ , (6)
where the rows of the (n − 1) × n matrix B form an orthonormal basis for the linear subspace
L = {a ∈ Rn : a>1n = 0} and ‖·‖ denotes the Euclidean norm. The LR test rejects H0 if S is small
enough, or equivalently, since S is non-increasing in R, if R is large enough.
The model predicts that the mean vector has the form α1n+βx, so that the centered and scaled
prediction from the model equals B(α1n + βx)/‖B(α1n + βx)‖ = (Bx)/‖Bx‖ = x˜ in the basis B.
Furthermore, y˜ contains the standardized (centered and scaled) observations, so that both x˜ and
y˜ lie on the unit sphere. The centering and scaling implies that R is the correlation coefficient
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between observations and predictions and R2 the coefficient of determination (Seber and Lee, 2003,
Section 4.4). Since the inner product between the two unit vectors x˜ and y˜ increases monotonically
with the distance between the two vectors, the LR test rejects H0 if the standardized predictions
are close enough to the standardized observations.
Let d = n − 2 denote the degrees of freedoms and S = {s ∈ Rd+1 : ‖s‖ = 1} the d-dimensional
unit sphere (some authors call it the d+ 1 dimensional unit sphere since it is in Rd+1). Then x˜ ∈ S
and y˜ is uniformly distributed on S under H0, which can be seen as following: the assumption of
H0 is y ∼ N (α1d+2, σ2Id+2); hence By ∼ N (αB1d+2, σ2BB>) with αB1d+2 = 0d+1 (since 1d+2 is
orthogonal to L) and BB> = Id+1; hence By is spherically symmetric (Fang and Zhang, 1990) and
y˜ is uniformly distributed on S.
The p-value of the LR test is P0(R > r), with r for the observed value of R and P0(·) the
probability calculated under the null hypothesis H0 (since the distribution of R does not depend
on the parameter α, we may assume µ = 0n for P0). If we define the neighborhood around a point
s ∈ S (a spherical cap) as Csr = {t ∈ S : s>t > r}, then P0(R > r) is equal to the probability that
y˜ is in the spherical cap around x˜ defined by r under H0: P0(R > r) = P0(y˜ ∈ Cx˜r); see Figure 1.
As y˜ is uniformly distributed on S under H0 it follows that P0(y˜ ∈ Cx˜r) = |Cx˜r| / |S| where |·| is the
(d-dimensional) volume of a set on S. Since the volume of the spherical cap |Csr| does not depend
on the point s ∈ S, we will simply write |Cr| for such a volume.
Using the equations for the volumes of spheres and of spherical caps (Li, 2011), we get
P0(R > r) =
|Cr|
|S| =
1− F (r2, 1/2, d/2)
2
, for r ∈ [0, 1], (7)
where F (·, a, b) denotes the cdf of the beta distribution with parameters a, b ∈ R+. The equation
when r ∈ [−1, 0) follows from |Cr| = |S| − |C−r|.
Of course, in this section we have only derived a test equivalent to the standard t-test for the
linear model. However, the considerations will be useful in the following sections.
2.2.2 Single nonlinear dose-response model
We now consider again the case of a single hypothesis I = {i}, but generalize to the situation,
where the parameter space Γi no longer consists of a single point. We write Γ = Γi and xÈ = xÈ,i.
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Figure 1: Standardized prediction x˜, standardized observation y˜, and spherical cap Cx˜,r (gray area) when
d = 1 (left side) and when d = 2.
0
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Figure 2: Left plot: Observed point y (open circles) and the exponential curves z 7→ exp(z/È), with
z ∈ [0, 3] for the four values È = 0.1, 0.7, 1.6, 10 plotted in the zero-one standardization; the curve for
È = 0.1 is the lowest (most convex) curve, while the curve for È = 10 is the topmost (almost linear)
curve. Middle plot: tubular neighborhood Tr (gray area) around the curve M = {x˜È : È ∈ [0.1, 10]} (black
line) for the model x
(k)
È = exp(z(k)/È) with z(k) = k − 1 for k = 1, 2, 3. Right plot: model curve for the
counterexample at the end of Section 2.2.3.
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By the considerations in the last section, the LR statistic for a fixed value È ∈ Γ equals RÈ = x˜>È y˜,
with x˜È = (BxÈ)/‖BxÈ‖. Therefore, the LR statistic of H0 against Hi equals infÈ∈Γ S(RÈ) = S(R)
with R = supÈ∈ΓRÈ since S is continuous and non-increasing in R.
Write again r for the observed value of R, define the model set M = {x˜È : È ∈ Γ} of the
standardized prediction that are possible under Hi, and define the tubular neighborhood Tr =
Tr(M) =
⋃
s∈MCsr around M. Then it follows from the uniform distribution of y˜ that
p = P0(R > r) = P0(y˜ ∈ Tr) = |Tr| / |S| .
The volume |S| of the unit sphere is straightforward to calculate. Hotelling (1939) gives explicit
equations for |Tr| when M is a closed curve that satisfies certain regularity conditions (essentially
the nonlinear transformation xÈ needs to be sufficiently smooth) . These results have been extended
to more general manifolds M; see, for example, Naiman (1990) and Gray (2004), and the references
therein.
The middle plot of Figure 2 illustrate this construction for the exponential model x
(k)
È =
exp(z(k)/È) with z(k) = k−1 for k = 1, 2, 3. Here and in the following, we will write x(k) and z(k) for
the k-th elements of the vectors x and z. Assume that we observe a point y = (−0.6, −0.2, 0, 0.8)>.
The correlation RÈ = x˜
>
È y˜ is maximized when È = 1.7. Four points x˜0.1, x˜0.7, x˜1.6 x˜10, which are
equally spaced on M, are shown together with their spherical caps; the tubular neighborhood Tr is
generated by moving the spherical cap along the curve M. Note that equal spacing of points on M
leads to unequally parameter values È, this is due to the nonlinearity of the model function.
Since RÈ is invariant under affine transformations of xÈ and y, we may scale them to the unit
interval (“zero-one standardization”), as shown in the left-hand side of Figure 2.
2.2.3 χ2 critical values
Before we continue to the case of multiple models in the next section, we will consider what could
happen if we would simply ignore the identifiability issue and would assume that the statistic
−2 logS is asymptotically χ2 distributed.
The critical value of such a test would depend only on the number of parameters in the model,
but not on the area of on sphere covered by the model. One can construct an example that shows
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that such a test can not control the type-I error in general: in fact, for any critical value q ∈ R+ of
the statistic −2 logS, there exists a model so that the resulting test always rejects (has type-I error
1). The idea is to choose the model in such way that the standardized predictions form a curve that
comes arbitrarily close to any point on the unit sphere. In Appendix B we give the model equation
for a model function that fulfills these requirements, see also the right-hand side of Figure 2, which
gives a graphical illustration of this model.
2.2.4 Multiple nonlinear dose-response models
The case of multiple models can be treated along the lines of a single model, just by forming the
union of the dose-response model shapes on the unit sphere: the multiple models can be collapsed
into a single big model, so that the case of a candidate set of models is along the lines of the single
model. From a multiple testing perspective a max-test is being performed, i.e. the maximum being
over the different candidate dose-response models.
In more detail, the LR statistic is a monotonous function of the statistic
R = max
i∈I
sup
Èi∈Γi
x˜>Èi,iy˜, with x˜Èi,i = (BxÈi,i)/‖BxÈi,i‖.
Equivalently, we can write R as R = supÈ∈Γ′ x˜
>
È y˜ for a single (composite) model
Γ′ =
⋃
i∈I
{
Γi × {i}
}
, x˜(Èi,i) = x˜Èi,i.
If we define M = {x˜È : È ∈ Γ′} and Tr(M) for this composite model, then the task reduces to the
calculation of the volume |Tr|, since
P0(R > r) = |Tr| / |S| .
Analytic methods developed for the case of a single model can no longer be used as the different
models might have intersecting curves on the unit-sphere (see Figure 3 for an illustration), which
is why specialized numerical methods need to be developed to calculate the associated tubular
volumes.
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M1
Tr1
M2
Tr2
Figure 3: Standardized predictions Mi = {x˜i,Èi : Èi ∈ Γi} and tubular neighborhoods Tri = Tr(Mi) for the
models x
(k)
1,È = cos(z
(k) + È) and x(k)2,È = (z
(k))È/(z(k))È + 1.5), where Γ1 = [pi, (5/4)pi] and Γ2 = [10
−3, 5],
when z = (0, . . . , 3)>. Due to the overlap between the two neighborhoods, the volume of the combined
tube, |Tr1 ∪ Tr2|, is smaller then the sum of the two volumes, |Tr1|+ |Tr2|.
In addition to the overall p-value p = P0(R > r), the multiplicity-adjusted p-values pi = P0(R >
ri) for the individual hypothesis Hi, for i ∈ I, are also of interest, where ri is the correlation between
the observations and the best predictions under the hypothesis Hi.
This “multiplicity” penalty has a direct geometric interpretation: if the candidate set of dose-
response models gets larger, the standardized predictions cover larger parts on the unit sphere;
consequently, the tube around the standardized model predictions has to get thinner if the volume
|Tr| (and therefore the type-I error) should be kept constant.
2.3 Numerical calculation of tubular volumes
This section describes an algorithm motivated by importance sampling to approximate the proba-
bilities P0(R > r) = P0(y˜ ∈ Tr), to obtain p-values or a critical value rcrit for the test statistic R.
As discussed earlier, under the null hypothesis, y˜ is uniformly distributed on the sphere, so that
P0(R > r) =
∫
Tr dς, with ς the uniform probability measure on S. In addition to p-values and the
critical value, we are also be interested in calculating the power P1(R > r) = P1(y˜ ∈ Tr), for a
critical value r, with P1(·) a probability calculated under some alternative hypothesis. By argu-
ments due to Pukkila and Rao (1988), under alternative hypotheses, y˜ follows an angular Gaussian
distribution on S, which means that P1(R > r) =
∫
Tr f dς, where f : S → R is the density of the
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angular Gaussian density (of course, under the null-hypothesis f ≡ 1.)
Let us motivate the algorithm by considering a naive sampling approach. If we draw a sample
U1, . . . , Uκ uniformly from S, then
∫
Tr f dς ≈
∑κ
k=1 1{Uk ∈ Tr}f(Uk)/κ. However, since Tr is
only implicitly defined by the nonlinear models, deciding if a point Uk belongs to Tr requires the
computationally expensive calculation of the maximum-likelihood estimates for each of the nonlinear
models.
A better approach is to restrict sampling to Tr instead of sampling from the whole sphere S.
If one can construct a probability distribution supported only on Tr with known density g with
respect to ς, and generate a sample V1, . . . , Vκ according to this distribution, then we could use
importance sampling to obtain the approximation∫
Tr
f dς ≈ 1
κ
κ∑
k=1
f(Vk)
g(Vk)
. (8)
However, calculating such density g is challenging. The approach proposed in this paper is to sample
points V1, . . . , Vκ in such a way that even if we can not calculate g exactly, we can approximate g
from the sample itself. The main idea for sampling only within Tr is to first sample a model i from
the m models with equal probability, then sample a value È from Γi according to some convenient
distribution (for example, the uniform distribution if Γi has finite volume) and take W = x˜È,i. Then
one samples a point V from GW , the uniform probability distribution on the spherical cap CWr
around W with radius r. It is possible to approximate the density g underlying this proposal
sampling mechanism (see the Appendix C for details), which is needed to calculate the importance
ratios in (8).
Note that in the strict sense however this is not an importance sampling algorithm, as the
proposal density g as well as integral are determined from the same sampled values. In Appendix C
the consistency of the sampling scheme is proved. That means that the approximation error of the
algorithm can be made arbitrarily small by increasing the number of sampling replicates κ. The
number of simulations can be chosen by monitoring the Monte Carlo standard error, to obtain the
desired precision.
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2.4 Comparison to MCP-Mod
The multiple contrast test of the MCP-Mod procedure (Bretz et al., 2005) can be viewed as a
discrete analogue of the likelihood-ratio approach presented here, as each model is restricted to a
finite number of possible shapes in MCP-Mod.
Even in the case of a finite number of possible shapes (when both approaches are applicable), the
likelihood-ratio test seems preferable due to the following argument. The t-test for testing β = 0 is
uniformly most powerful invariant with respect to affine transformations (Lehmann and Romano,
2008, Chapter 7). While the likelihood-ratio test is equivalent to the t-test, the corresponding
contrast test statistic is invariant but differs from the t-test in the variance estimate; hence it is not
in general admissible (although in this setting power gains by an LR test are unlikely to be large).
3 Applications
In this section we will use data from a dose-response clinical trial to illustrate the methodology.
One of the objectives of such trials is to test for a dose-response effect, that is, whether the dose-
response is flat or not. Motivated by the data, we define some scenarios and compare the approach
to alternative trend tests: Section 3.2 considers a single candidate model; Section 3.3 considers a
candidate set of models.
In all examples considered p-values and power values were calculated using a Monte Carlo
standard error of at most 0.001, or when a maximum sample of 106 samples was reached in the
algorithm. Calculation of the critical value was done using root-findung under the null-hypothesis.
3.1 Dose-Finding Example
The purpose of this section is to illustrate the methodology on a real data set and compare it
to the MCP-Mod methodology. The section also illustrates how the critical value (and thus the
multiplicity adjustment) depends on the complexity of the candidate set of models.
The used data set is available in the DoseFinding R package under the name biom. The data
comes from 100 patients allocated equally to a placebo and four treatment arms with dose levels
13
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Figure 4: Response curves in the candidate set. The curves were standardized to have effect 0 at dose-level
0 and effect 1 at dose-level 1 (the “zero-one” standardization from Figure 2): (a) depicts Emax models for
[0.001, 1.5] (gray area) and [0.001, 10] (gray and dark gray area combined). (b) depicts curves corresponding
to the used candidate models: Emax, linear and exponential (c) depicts the candidate curves used for the
MCP-Mod methodology
0.05, 0.2, 0.6, 1.
To observe the impact of the richness of the candidate set on the critical value (i.e. the resulting
multiplicity adjustment), we will sequentially increase the set of candidate models. We start with
the Emax model α+β z(k)/(z(k)+È), where the interval Γ = [0.001, 1.5] was chosen for the parameter
È. This interval covers a wide range of possible shapes underlying the Emax model. This can be
seen, when plotting and overlaying the resulting (“zero-one” standardized) response curves; see
Figure 4 (a). The boundaries of the polygon correspond to È equal to 0.001 and 1.5. When using
a significance level of 5% one-sided, the resulting critical value is 0.197. When raising the upper
limit of È to 10, although this results in a much larger interval for È, the critical value only goes
up to 0.199. The reason is that the standardized model predictions do not cover much additional
area on the unit sphere. This can also be seen in Figure 4 (a) in the dark gray area: Due to the
nonlinearity, the additional flexibility on the parameter space (by increasing the upper bound to
10) does not lead to a major increase in flexibility of the model shapes.
Now suppose we would like to add a linear model α+ βz(k) to the candidate set of models. The
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Figure 5: Fitted dose-response functions for biom data-set with 95% pointwise confidence intervals, the
means at each dose with 95% confidence intervals are also shown.
linear model does not use a dose transformation and it represents only a single shape; see also the
linear increasing line in Figure 4 (b). Therefore, adding this model does not make the candidate
set much broader in terms of shapes, and the critical value only increases to 0.200. When adding
an exponential model of form exp(z(k)/È) − 1 with parameter bounds [0.1, 2], this leads to a more
pronounced extension of the possible predictions. This is also reflected in the critical value, which
goes up to 0.210. Figure 4 (b) shows the possible shapes that will be used for the LR test.
So there is a direct, intuitive connection between the critical value and the complexity of the
candidate model shapes. The more parts of the unit sphere are covered the larger the multiplicity
penalty. On the other hand, when an additional shape is added that is similar to other shapes that
are already in the candidate set, the critical value does not increase noticeably, due to the overlap
of tubes.
Fitting the dose-response models with the necessary parameter constraints can be done using the
fitMod function from the DoseFinding R package. The fitted dose-response functions are shown
in Figure 5
The parameter estimates of the models can be found in Table 1, in addition to the p-values for
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Table 1: Results of likelihood-ratio test. The test statistic R is the correlation between the observation
and the best model prediction. p-value∗ is the p-value taking into account the fact that a candidate set of
models was used (multiplicity adjustment for the multiple models), while p-value∗∗ is the p-value within
the respective model class (no adjustment for the multiple models).
Model Parameter estimates test-statistic p-value∗ p-value∗∗
Emax (È ∈ [0.001, 1.5]) α = 0.32, β = 0.75, È = 0.14 0.335 0.001 0.001
Linear α = 0.49, β = 0.56 0.287 0.006 0.002
Exponential (È ∈ [0.1, 2]) α = 0.51, β = 0.83, È = 2.00 0.276 0.009 0.004
testing β = 0 versus β > 0, for each of the three models. It can be seen that the p-values for the
models, considering all three models as candidate set, are all smaller than 0.01. Of course, this is
also true for the p-values that result from considering each model class separately.
For comparison we will also apply the MCP-Mod procedure. Similar to Bretz et al. (2005),
we choose an Emax shape with È = 0.2, a linear shape and two exponential shapes, one with
È = 0.5/ log(6) and the other with È = 0.15. The candidate shapes of the MCP-Mod procedure are
presented in Figure 4 (c). The results shown in Table 2 have been calculated using the MCTtest
function in the DoseFinding package. One can see that the Emax and linear model have p-values
< 0.01 similar to the LR test. However, the two exponential shapes have p-values > 0.025, despite
the fact that a trend could be detected using the LR test for the exponential model. The reason
is that neither of the two È values fits the data well. If the exponential model for È = 2 would
have been included in the set of MCP-Mod candidates also a p-value smaller than 0.01 would be
observed.
After establishing the existence of a dose-response effect, one can continue by either selecting
or averaging models to estimate the dose-response curve and the target dose of interest; a detailed
discussion of these topics can be found in Schorning et al. (2015).
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Table 2: Results of MCP-Mod testing approach.
Shape test-statistic p-value
Emax (È = 0.2) 3.464 0.001
Linear 2.972 0.004
Exponential (È = 0.15) 2.218 0.028
Exponential (È = 0.5/ log(6)) 1.898 0.056
3.2 Power calculations for a single Emax model
In this section, we compare the power of the LR test to tests that are optimal for specific values of
È: assume that the true model is an Emax model with a parameter value È; then, as discussed in
Section 2.4, the t-test of β = 0 versus β > 0 in the linear model y ∼ N (α1n + βxÈ, σ2In) using the
true parameter È, is uniformly most powerful invariant. We will refer to this test as locally optimal
for È. These tests provide a useful upper bound for the performance of the likelihood-ratio test.
Consider again the dose-response trial with dose levels 0, 0.05, 0.2, 0.6, 1. We take 20 observa-
tions per dose level and choose the non-centrality parameter δ = β‖BxÈ‖/σ (Seber and Lee, 2003,
Section 6) so that the locally optimal test has power 80% for a one-sided type I error of 5%.
For scenarios with different È values from Γ = [0.001, 1.5], we look at the power of a LR
test with È ∈ Γ, and the power of locally optimal tests for the four parameter values È =
0.001, 0.035, 0.159, 1.5. These parameter values are chosen so that the corresponding points xÈ
are separated by equal distances along the model curve M = {x˜È : È ∈ Γ}. The critical value of
the LR test is given by 0.197. In Figure 6 it can be seen that the LR test achieves a power above
70% over the whole range of Γ and is rather close to the respective locally optimal test. The power
of the each locally optimal tests decreases markedly, when the parameter È is mis-specified. For
example the optimal test for È = 0.001 has only around 50% power when the true value is È = 0.24.
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Figure 6: Power values of different test procedures in dependence of the true parameter value È in the
Emax model x
(k)
È = z(k)/(z(k) +È) with 20 observations for each of the dose levels 0, 0.05, 0.2, 0.6, 1. Power
values of the locally optimal tests for È values 0.001, 0.035, 0.159, 1.5 are shown with dotted and dashed
lines. Power values of the likelihood-ratio test with Γ = [0.001, 1.5] are shown as solid line. The axis for the
true È values is scaled so that equal distances on the axis correspond to equal distances along the model
curve È 7→ x˜È of standardized predictions.
3.3 Power calculations for multiple models
We now define five scenarios for the true underlying mean vector: 1) a linear model; 2) an Emax
model with parameter È = 0.2; 3) an exponential model with parameter È = 0.1; 4) an exponential
model with parameter È = 0.5/ log(6); and 5) a sigmoid Emax model of the form x = z4/(z4+0.054).
We choose the non-centrality parameter so that in each scenario, the locally optimal test has a
power of 50% or 80% for a one-sided type I error of 5%. Note that these locally optimal tests are
in practice “unachievable”, as they use information about the true dose-response model class and
the true parameter È.
The LR test uses the following candidate models: the linear model, the Emax model with
Γ = [0.001, 1.5], and the exponential model with Γ = [0.1, 2]. The critical value of the LR test is
given by 0.210.
For comparison, we consider three multiple contrast tests. First we use Williams contrasts and
Marcus contrasts (Williams, 1971; Marcus, 1976), as implemented in the multcomp R package. Both
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Table 3: Power (in percent) of different test procedures The five scenarios are: 1) a linear model; 2) an
Emax model with parameter È = 0.2; 3) an exponential model with parameter È = 0.1; 4) an exponential
model with parameter È = 0.5/ log(6); and 5) a sigmoid Emax model of the form x = z4/(z4 + 0.054). The
non-centrality parameter is chosen so that a local optimal test has either 50% power (first 5 rows) or 80%
power (last 5 rows).
Locally optimal test for scenario
Power Scenario LR 1 2 3 4 MCP-Mod Williams Marcus
50 1 (Linear) 43.3 50.0 44.1 39.4 45.1 46.8 34.9 43.0
2 (Emax) 43.4 44.1 50.0 25.3 32.1 44.1 41.1 43.8
3 (Exp 1) 39.4 39.4 25.3 50.0 48.8 44.1 28.0 37.7
4 (Exp 2) 41.6 45.1 32.1 48.8 50.0 46.1 30.6 40.2
5 (Sigm) 41.2 30.7 44.8 15.1 19.5 36.2 44.0 41.2
80 1 (Linear) 73.4 80.0 73.0 66.6 74.3 76.8 61.5 72.9
2 (Emax) 73.4 73.0 80.0 43.0 55.1 74.5 69.7 73.5
3 (Exp 1) 69.9 66.6 43.0 80.0 78.6 74.5 52.2 67.8
4 (Exp 2) 72.1 74.3 55.1 78.6 80.0 76.2 56.0 70.3
5 (Sigm) 71.1 52.9 73.9 23.2 31.9 65.0 73.6 71.0
are known to be powerful trend tests. In addition, we use a multiple contrast test with four model-
based contrasts (as in MCP-Mod), where the contrasts are optimized to detect the true underlying
simulation scenarios 1-4 (see Pinheiro et al. (2014) for details on how to calculate these optimal
contrasts). This is unrealistic, as in practice the value of È for each model is unknown, but it gives
a useful benchmark. Scenario 5) is included to investigate the behaviour for a model shape that is
neither part of the LR test nor MCP-Mod set of candidate shapes.
In Table 3 one can observe that the performance of the locally optimal tests decreases for the
scenarios they are not optimized for, only the locally optimal test corresponding to the linear shape
gives a surprisingly good overall performance. Among the multiple contrasts tests the MCP-Mod
19
contrasts, which use information about the true shapes, perform best, apart from the mis-specified
scenario 5, where both Williams and Marcus contrasts perform better.
The LR test gives a more robust overall performance. For scenarios 1-4 the power is slightly
lower than for the MCP-Mod contrasts, despite the fact that a richer candidate set of models is
used. For scenario 5 one can however see that the LR test outperforms the MCP-Mod contrasts.
This is most is due to increased robustness (i.e. increased flexibility in model shapes) of the LR
test compared to the MCP-Mod contrasts, so that for this shape not included in the candidate set
a better performance is obtained.
4 Conclusions
In this manuscript, we have considered the problem of detecting a dose-related trend based on a
set of candidate dose-response models.
The problem is not identifiable asymptotically and the standard asymptotic χ2 distribution
of the likelihood-ratio statistic does not apply. Furthermore one can show that using a critical
value that depends only on the number of parameters in the candidate models and not the model
complexity (i.e. the parts covered on the unit sphere) may lead to an arbitrarily large type-I error
inflation. To avoid this, we work with the exact small-sample distribution of the likelihood-ratio
statistic. Based on a geometric interpretation of the test statistic due to Hotelling, an sampling
algorithm has been developed to approximate the exact distribution of the test statistic.
This work extends the previously available methods for dose-response testing in several respects.
The multiple contrast tests in MCP-Mod use a fixed set of guesstimates of the nonlinear parameters
È in the testing step, but then in the modelling step estimates those parameters from the data. We
do not require that the parameters in the nonlinear model part are fixed guesstimates, but allow to
vary in a defined interval.
An advantage over alternative approaches to derive the distribution of the likelihood ratio test
statistic under multiple models (such as those in Dette et al. (2015) and Baayen et al. (2015)) is
that we work with the finite sample distribution instead of the asymptotic distribution. In addition
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to rejection probabilities under the null hypothesis, we also consider rejection probabilities under
alternatives. This allows to perform power calculations and thus sample-size calculations at the
design stage of an experiment, which is of crucial importance in clinical trials.
The developed methods for calculation of the distribution of the LR test could be of interest
beyond dose-response analysis. Nonlinear models, where a test of trend is of interest, appear in many
areas of applied sciences such as biology and economics (e.g. change point analysis or harmonic
regression).
We have assumed that the residuals are normally distributed. The extension to elliptically
contoured distributions is possible directly (Fang and Zhang, 1990; Gupta and Varga, 1993); for
other distributions, components of the likelihood-ratio statistic may not be restricted to the unit
sphere anymore, but the general approach may still be applied in some situations: for example,
Diaconis and Efron (1985) show that the rejection regions of a test for independence in a two-way
contingency table are tubular neighborhoods on a simplex on which the test statistic is uniformly
distributed under the null hypothesis.
We have also assumed that under the correct model, residuals are independent. The extension
to the case of a known correlation structure appears straightforward. More fundamental extensions,
such as allowing random effects in addition to the fixed effects, could also be considered.
Another extension would be to test more complicated null hypotheses. For example, a test for
a hypothesis HI versus an alternative HJ where I ⊆ J ⊆ {1, . . . , 2m} allows to test individual
parameters of a nonlinear model, such as the Hill parameter of the sigmoid Emax model.
The rationale for developing a specialized numerical algorithm for this problem is that direct
simulation under the null hypothesis is computationally difficult, since it involves multiple iterative
optimizations for each simulation replicate with a poorly identified nonlinear parameter È. By
using a form of importance sampling it is not necessary to perform nonlinear optimization for the
sampling replicates. Note that the developed sampling algorithm might be of interest in general
for calculation of the volume of tubes. At the moment dimensionality that the algorithm works on
grows with the number of observations, an improvement of the algorithm would be to work with
sufficient statistics instead of raw data. This makes the algorithm more efficient, but also more
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complicated. We also note here that it is numerically advantageous to replace random samples by
quasi-random samples (as discussed for example in Fang and Wang (1994)), in which case quasi
importance sampling gives a quadrature rule for functions on tubular neighborhoods.
This paper is primarily concerned with testing for a dose-response effect, which is only one of
the question of interest in dose-finding studies. Once a dose-response effect has been established the
following questions are to estimate the dose-response curve and target doses of interest, so a further
topic to explore is the relation between testing and estimation. For (frequentist) model averaging,
the predictions are most commonly weighted according to either the AIC or the BIC of the models
(see among others Schorning et al. (2015)). Both of these criteria penalize models only according
to the number of parameters in the model. We have seen that the number of parameters is, at least
for testing, a poor surrogate for the model complexity (the flexibility of the predictions that are
possible under a model). Maybe geometric considerations can be used to penalize complex models
in a more meaningful way.
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Appendix A: Likelihood-ratio statistic for a single parameter value
Theorem 1. The LR statistic for H0 : β = 0 against Hi : β ≥ 0 in the linear model y ∼
N (α1n + βx, σ2In) has the form S(R) = (1− 1{R > 0}R2)n/2, where R is defined in Equation (6)
in the paper.
Proof. Note first that R = (Bx)>(By)/(‖Bx‖‖By‖) = (Cx)>(Cy)/(‖Cx‖‖Cy‖), with C = In −
n−11n1>n the centering matrix.
Let us first deal with a trivial case:
Case 1: If y is constant (that is, if y = α1n for some α ∈ R), then R = 0 (since Cy = 0n) and
S = 1 (since the likelihood is maximized for β = 0 both under H0 and under Hi).
Assume from now on that y is non-constant. Then the LR statistic has the form (Seber and
Lee, 2003, p. 99) S = (1− T )n/2 with
T = 1− minα∈R,β∈R+‖y − α1n − βx‖
2
minα∈R‖y − α1n‖2 = 1−
f(βˆ+)
f(0)
,
where f(β) = ‖C(y − βx)‖2 and βˆ+ = arg minβ∈R+ f(β) (with f(0) > 0 since y is non-constant).
Define βˆ± = arg minβ∈R f(β). From βˆ± = (‖Cy‖/‖Cx‖)R, Seber and Lee (2003, p. 139), it
follows that
βˆ± > 0 ⇐⇒ R > 0. (9)
Let us distinguish two cases:
Case 2: If R ≤ 0, then βˆ± ≤ 0 and βˆ+ = 0 (since f is quadratic in β), so that
T = 1− f(0)/f(0) = 0. (10)
Case 3: If R > 0, then βˆ± > 0 and βˆ+ = βˆ±, so that
T = 1− f(βˆ±)/f(0)
From
‖Cy − (‖Cy‖/‖Cx‖)R(Cx)‖2 = ‖Cy‖2 − 2 (‖Cy‖/‖Cx‖)R(Cx)>(Cy)︸ ︷︷ ︸
‖Cy‖2R2
+ (‖Cy‖2/‖Cx‖2)R2‖Cx‖2︸ ︷︷ ︸
‖Cy‖2R2
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we get f(βˆ±) = ‖Cy‖2(1−R2) and
T = 1− ‖Cy‖
2(1−R2)
‖Cy‖2 = R
2. (11)
Putting Case 2 and Case 3 together, we obtain T = 1{R > 0}R2, and combining all three cases,
we get
S(R) = (1− 1{R > 0}R2)n/2. (12)
Appendix B: Counterexample: χ2 critical values
Consider, the model
xÈ = B
+x˜È, È ∈ Γ = [0, 2pi],
with B+ the Moore-Penrose pseudoinverse of B, and
x˜(k)È = cos
(
1{k > 1}λk−2È) d∏
`=k
sin
(
λ`−1È
)
, k = 1, . . . , d+ 1,
for some constant λ ∈ N. The standardized predictions, x˜È, are the Cartesian coordinates of a
point with spherical coordinates È, λÈ, . . . , λd−1È. Since supψ∈[0,2pi]d infÈ∈Γ‖ψ − (È mod 2pi, λÈ mod
2pi, . . . , λd−1È mod 2pi)>‖ → 0, also inf y˜∈S supÈ∈Γ y˜>x˜È → 1, as λ→∞. Therefore, for any q, we can
choose a constant λ so that R > (1− exp(−q/n))1/2 for all y˜ ∈ S, which ensures that −2 logS > q.
The plot in the right-hand side of Figure 2 in the paper illustrates the construction when d = 2.
As È goes from 0 to pi, the spiral curve È 7→ x˜È takes λ rotations around the sphere. For any r < 1,
one can choose λ large enough to make the tubular neighborhood around M cover the complete
sphere. Note that both of the models in Figure 2 have the same number of parameters but their
complexities (in terms of the possible predictions) are vastly different.
Appendix C: Details on the numerical calculation of tubular volumes
Assume that we have some way to sample a point W with support M. Let us say that this point
has distribution H on M, even if we do not know H explicitly. For the sake of illustration, here is
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one simple way to sample such a point: start by selecting a model i from the m models with equal
probability, then sample a value È from Γi according to some convenient distribution and finally
take W = x˜È,i.
Next, we sample a point V from GW , the uniform probability distribution on the spherical
cap CWr. The joint distribution is P (V ∈ T,W ∈ M) =
∫
M
Gw(T )dH(w), for Borel sets T ⊆ Tr
and M ⊆ M. By Fubini’s theorem, ∫
M
Gw(T ) dH(w) =
∫
T
∫
M
gw(v) dH(w) dς(v), with gw(v) =
1{w ∈ Cvr}/ς(Cvr) the density of Gw with respect to ς. Let us define cr = ς(Cvr) = |Cr| / |S|. The
value of cr is given in Equation (7) in the main text. Then, the random point V has density
g(v) =
1
cr
∫
M
1{w ∈ Cvr} dH(w) = 1
cr
P (W ∈ Cvr).
If we repeat this procedure κ times, we obtain a sample (V1,W1), . . . , (Vκ,Wκ). Approximating
P (W ∈ Cvr) by relative frequencies gives g(v) ≈ |{j : Wj ∈ Cvr}| /(κcr). In this way, we arrive at
the approximation ∫
Tr
f dς ≈ cr
κ∑
k=1
f(Vk)
|{j : Wj ∈ CVkr}|
. (13)
Note that we work with points on the d-dimensional unit sphere, which becomes difficult when
the sample size becomes large. It is, however, possible to modify the algorithm, and work with
sufficient statistics instead of raw data. To keep the presentation brief, the details are not given
here. Algorithm 1 outlines the main steps of the procedure.
for k ← 1 to κ do
sample Wk from the distribution H on M;
sample Vk from GWk on CWk,r;
end
for k ← 1 to κ do
Calculate mk = |{j : Wj ∈ CVkr}|;
end
Result: cr
∑κ
k=1 f(Vk)/mk
Algorithm 1: Sampling algorithm
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Theorem 2 below shows that the right-hand side of Equation (13) converges in probability to
the left-hand side as κ → ∞. Hence, the approximation error can be made arbitrarily small by
increasing the number of sampling replicates κ.
Definition 1. In the following, we will call a family Ynj, with j = 1, . . . , n and n = 1, 2, . . . , of
random vectors a triangular arrangement, if for each n, the random vectors Yn1, . . . , Ynn are iid and
have finite expectations and variances.
Theorem 2. Let M be a Borel set on S and let Tr denote the tubular neighborhood around M with
radius r. Consider a sequence wn in M so that |{j : 1 ≤ j ≤ n and wj ∈ Cvr}| → ∞ as n→∞ for
each v in the interior of Tr. Also consider a sequence of independent random vectors Vn ∼ U(Cwn,r),
uniformly distributed on the spherical cap Cwn,r. Let f : S → R+ be Borel and bounded. Define
the sequence of functions gn : Trn → R+, on Trn = ∪nj=1Cwj ,r, by gn(v) = (nψn(v)ς(Cvr))−1 with
ψn(v) = 1/ |{j : 1 ≤ j ≤ n and wj ∈ Cvr}| and ς the uniform probability measure on S. Also define
the random variables Xn = f(Vn)/gn(Vn) and Sn = (X1 + · · ·+Xn)/n. Then Sn P→
∫
Tr f dς.
Proof. Consider the triangular arrangements Knj and V
′
nj and X
′
nj, where Knj ∼ U({1, . . . , n}),
where V ′nj | (Knj = k) ∼ U(Cwk,r), and where X ′nj = f(V ′nj)/gn(V ′nj). Define S ′n = (X ′n1 + · · · +
X ′nn)/n. Due to Lemma 1 below, it suffices to show that E(S
′
n)→
∫
Tr f dς and Var(S
′
n)→ 0.
First, the argument for E(S ′n) →
∫
Tr f dς. For each n, the variables X
′
n1, . . . X
′
nn are iid; hence
E(S ′n) = E(X
′
n1). Since V
′
n1 has density gn on Trn (with respect to ς),
E(X ′n1) = E
(
f(V ′n1)
gn(V ′n1)
)
=
∫
Trn
f(v)
gn(v)
gn(v)dς(v) =
∫
Trn
f dς.
Now Tr,1 ⊆ Tr,2 ⊆ . . . is an increasing sequence of subsets of Tr, and |Tr \ Trn| → 0 by the
assumptions on the sequence wn; therefore, by the monotone convergence theorem, E(S
′
n) =∫
Tr 1{v ∈ Trn}f(v) dς(v)→
∫
Tr f dς.
Second, the argument for Var(S ′n)→ 0. Integrating with respect to the density gn of V ′n1 gives
Var(X ′n1) = E
(
(X ′n1)
2
)− (E(X ′n1))2 ≤ ∫
Trn
f(v)2
gn(v)
dς(v).
Let M = supv∈Trn f(v)
2ς(Cvr), which is finite since f is bounded. Then Var(X ′n1) ≤ nM
∫
Trn ψn dς.
Furthermore, Var(S ′n) = Var(X
′
n1)/n since X
′
n1, . . . X
′
nn are iid; thus Var(S
′
n) ≤ M
∫
Trn ψn dς. But
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ψn(v) → 0 for every v in the interior of Tr and the boundary of Tr has measure zero, so that
Var(S ′n)→ 0 by the dominated convergence theorem.
Lemma 1. Consider a sequence of independent random variables Xn and two triangular arrange-
ments Knj and X
′
nj, where Knj ∼ U({1, . . . , n}) and X ′nj | (Knj = k) d= Xk. Define Sn =
(X1 + · · · + Xn)/n and S ′n = (X ′n1 + · · · + X ′nn)/n. If E(S ′n) → α for some value α ∈ R and
Var(S ′n)→ 0, then Sn P→ α.
Proof. Fix a value  > 0. For every n ∈ N,
E(Sn) =
1
n
n∑
j=1
E(Xj) = E(E(X
′
n1 |Kn1)) = E(X ′n1) = E(S ′n).
Hence there exists an m ∈ N so that |E(Sn)− α| < /2, for all n > m.
It follows that for such n > m also P (|Sn − α| > ) ≤ P (|Sn − E(Sn)| > /2). By Chebyshev’s
inequality P (|Sn − E(Sn)| > /2) ≤ 4 Var(Sn)/2. Consequently, if Var(Sn)→ 0, then P (|Sn − α| >
)→ 0. And Var(Sn)→ 0 follows from
Var(Sn) =
1
n2
n∑
k=1
Var(Xk)
=
1
n
E(Var(X ′n1 |Kn1))
≤ 1
n
(
E(Var(X ′n1 |Kn1)) + Var(E(X ′nj |Kn1))
)
=
1
n
Var(X ′n1) = Var(S
′
n),
where the last line uses the well known equation for the conditional variance (see, e.g., Proposition
5.2 in Ross (2011)).
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